Skip to main content

Market Overview

Analyst Makes The Case For Ligand As A 'Core' Holding

Share:
Analyst Makes The Case For Ligand As A 'Core' Holding

Analysts at H.C. Wainwright & Co. continue to see Ligand Pharmaceuticals Inc. (NASDAQ: LGND) as a "core long term holding" for investors. The firm's Joseph Pantginis initiated coverage of the biopharmaceutical company with a Buy rating and $150 price target, mostly due to the company's business model.

Ligand seeks out value-based acquisitions of companies and technologies that have led to both current and anticipated revenue streams, Pantginis commented in his initiation note. This has also resulted in the company's reputation of reporting sustained profitability.

Ligand is also an early pioneer of contingent value rights for its acquisitions, the analyst continued. As such, earnings growth is supported by the company's increasing royalty streams that are also a "significant spreading out of risk" across multiple assets. On top of that, the reduced risk profile offers protection against downside to the stock on negative news relative to a typical biotechnology company.

tipranks.png

The company's management team also adds to the bullish story, Pantginis added. Specifically, John Higgins has been with the company since 2007 at which point Ligand was burning through approximately $100 million per year. Since then the executive oversaw a streamlining of operations and reduced expenses to approximately $20 million per year.

Bottom line, Ligand's stock is appealing to investors that are both revenue and earnings minded and want exposure to the biotechnology drug development sector with risk spread out across various assets.

Related Links:

25 Stocks Moving In Tuesday's Pre-Market Session

A Peek Into The Markets: U.S. Stock Futures Drop Ahead Of Fed Speakers

Latest Ratings for LGND

DateFirmActionFromTo
Feb 2021BarclaysMaintainsOverweight
Feb 2021Roth CapitalMaintainsBuy
Feb 2021HC Wainwright & Co.MaintainsBuy

View More Analyst Ratings for LGND
View the Latest Analyst Ratings

 

Related Articles (LGND)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas Price Target Initiation Top Stories Analyst Ratings Trading Ideas Best of Benzinga

Latest Ratings

StockFirmActionPT
DALJP MorganMaintains63.0
ALKJP MorganMaintains104.0
UALJP MorganMaintains58.0
SPGIBMO CapitalMaintains428.0
INFOBMO CapitalMaintains110.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com